首页> 外文期刊>Advances in Interventional Cardiology: Postepy w Kardiologii Interwencyjnej >Contrast-free percutaneous pulmonary valve replacement: a safe approach for valve-in-valve procedures
【24h】

Contrast-free percutaneous pulmonary valve replacement: a safe approach for valve-in-valve procedures

机译:无与伦比的经皮肺瓣膜置换:阀门阀手术的安全方法

获取原文
           

摘要

Introduction Percutaneous pulmonary valve replacement (PPVI) continues to gather pace in pediatric and adult congenital practice. This is fueled by an expanding repertoire of devices, techniques and equipment to suit the heterogenous anatomical landscape of patients with lesions of the right ventricular outflow tract (RVOT). Contrast-induced nephropathy is a?real risk for teenagers and adults with congenital heart disease (CHD). Aim To present a?series of patients who underwent PPVI without formal RVOT angiography and propose case selection criteria for patients who may safely benefit from this approach. Material and methods We retrospectively collected PPVI data from the preceding 2 years at our institution identifying patients who had been listed as suitable for consideration for contrast-free PPVI from our multidisciplinary team (MDT) meeting based on predefined criteria. Demographic, clinical, imaging and hemodynamic data were collected. Data were analyzed using SPSS. Results Twenty-one patients were identified. All patients had a?technically successful implantation with improvements seen in invasive and echocardiographic hemodynamic measurements. 90% of patients had a?bio-prosthetic valve (BPV) in situ prior to PPVI. One patient had a?complication which may have been recognized earlier with post-intervention RVOT contrast injection. Conclusions Zero-contrast PPVI is technically feasible and the suitability criteria for those who might benefit are potentially straightforward. The advent of fusion and 3D imaging in cardiac catheterization laboratories is likely to expand our capacity to perform more procedures with less contrast. Patients with bio-prosthetic valves in the pulmonary position may benefit from contrast-free percutaneous pulmonary valve implantation.
机译:引言经皮肺瓣膜更换(PPVI)继续收集儿科和成人先天性实践的步伐。这通过扩展的设备,技术和设备的扩展曲目来推动,以适应右心室流出道(RVOT)的病变患者的异质解剖景观。对比诱导的肾病是一种?青少年和成人具有先天性心脏病(CHD)的真正风险。目的旨在提出一系列患者,无需正式的RVOT血管造影,并为可能从这种方法安全受益的患者提出案例选择标准。我们在我们的机构核查前2年的PPVI数据核查患者,这些材料和方法在我们的机构识别患者中,患者根据预定标准从我们的多学科团队(MDT)会议中审议无染色的PPVI。收集了人口统计学,临床,成像和血液动力学数据。使用SPSS分析数据。结果鉴定了二十一名患者。所有患者均有一种?技术地成功地植入侵入性和超声心动图血液动力学测量中的改善。在PPVI之前,90%的患者在原位上有一个?生物假肢瓣膜(BPV)。一名患者有一个患者的复杂性,其可能先前识别,后介入射击造影剂注入。结论零对比PPVI在技术上是可行的,并且可能受益的人的适用标准可能是直截了当的。心脏导管插入实验室中融合和3D成像的出现可能会扩大我们的能力,以执行更少的对比度。肺命位中生物假体瓣膜的患者可能受益于无与伦比的经皮肺瓣植入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号